An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma

Dahlquist, Korbyn J V; Voth, Laura C; Fee, Amanda J; Stoeckman, Angela K.

doi:10.21873/anticanres.14628

Cited by 10 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, its mechanisms remain unclear. HCC releases various chemokines/cytokines to modulate the tumor microenvironment and regulates the proliferation and invasion of HCC cells 4,5 . The aim of this study was to investigate the direct effects of SGLT2i on tumor‐releasing chemokines/cytokines in human HCC cell lines.…”

Section: Figurementioning

confidence: 99%

“…Dahlquist et al . had shown that CXCL1 promoted the proliferation and invasion of rat HCC cells in an autocrine manner 4 . In addition, Kahraman et al .…”

Section: Figurementioning

confidence: 99%

“…had shown that CXCL1 promoted the proliferation and invasion of rat HCC cells in an autocrine manner. 4 In addition, Kahraman et al . reported that autocrine CXCL8 signaling is critical to activate the phosphatidyl‐inositol‐3 kinase/Akt/mammalian target of the rapamycin pathway, which is involved in the development and the progression of liver cancer stem cells.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells

et al. 2022

View full text Add to dashboard Cite

(a) Summary for SGLT2i‐induced alterations in 48 chemokines/cytokines in Hep3B and Huh7 cells. (b) SGLT2i‐induced changes in the medium CXCL1 level (each n = 4). (c) SGLT2i‐induced changes in the medium CXCL8 level (each n = 4). (d) SGLT2i‐induced changes in the medium CXCL10 level (each n = 4), (e) SGLT2i‐induced changes in the medium M‐CSF level (each n = 4). The SGLT2i‐induced significant changes in chemokines/cytokines are expressed as the percentage of control (the mean value of the control was set as 100%). CXCL, C‐X‐C motif chemokine ligand; G‐CSF, granulocyte colony‐stimulating factor; IL, interleukin; LIF, leukemia inhibitory factor; M‐CSF, macrophage colony‐stimulating factor; MIP‐1α, macrophage inflammatory protein‐1α; SDF‐1α, stromal‐cell‐derived factor‐1α; TNFα, tumor necrosis factor‐α; VEGF, vascular endothelial growth factor.

show abstract

Section: Figurementioning

confidence: 99%

“…Dahlquist et al . had shown that CXCL1 promoted the proliferation and invasion of rat HCC cells in an autocrine manner 4 . In addition, Kahraman et al .…”

Section: Figurementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In liver disease, CXCL1 has been found to have a role in alcoholic liver injury, steatohepatitis, and HCC ( 14 – 16 ), while previous studies have not examined the relationship between CXCL1 and ACLF. Our study found that expression of CXCL1 was dramatically increased in patients with HBV-ACLF as compared to that in healthy controls and patients with CHB and HBV-CC.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, an increasing number of studies have demonstrated that CXCL1 is involved in pathogenesis in liver disease, including in alcoholic liver injury, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) (14)(15)(16). However, little is known about the clinical relevance of CXCL1 in HBV-ACLF.…”

Section: Introductionmentioning

confidence: 99%

Serum CXCL1 Is a Prognostic Factor for Patients With Hepatitis B Virus–Related Acute-On-Chronic Liver Failure

et al. 2021

View full text Add to dashboard Cite

Purpose: Neutrophils and cytokines play a major role in the pathogenesis of acute-on-chronic liver failure (ACLF). We aimed to determine whether chemokine (CXC) ligand 1 (CXCL1), a key marker of neutrophil recruitment and activation, could predict the severity and prognosis of hepatitis B virus–related ACLF (HBV-ACLF).Methods: Hospitalized patients with HBV-ACLF were enrolled in a prospective study and stratified as survivors (alive at 28 days) and nonsurvivors (deceased at 28 days). Serum CXCL1 levels were measured in healthy controls, patients with chronic HBV, patients with HBV-related compensated cirrhosis, and patients with HBV-ACLF. Univariate and multivariable logistic analyses, Pearson correlation analysis, area under the receiver operating characteristic curve (AUROC), and Z tests were used to evaluate the performance of CXCL1 as a marker in HBV-ACLF.Results: Patients with HBV-ACLF had significantly higher serum levels of CXCL1 and neutrophil count than healthy controls and patients with chronic HBV or HBV-related compensated cirrhosis (P < 0.01, respectively). Among patients with HBV-ACLF, survivors had lower serum CXCL1 levels and neutrophil count than those of nonsurvivors (P < 0.001, P < 0.05, respectively). Serum CXCL1 level was positively correlated with neutrophil count (r = 0.256, P = 0.001), ACLF grade (r = 0.295, P < 0.001) and organ failure, including coagulation (r = 0.21, P = 0.005) and brain failure (r = 0.198, P = 0.008). Multivariable logistic analyses showed serum CXCL1 [OR (95% CI) = 1.017 (1.009–1.025), P < 0.001] was an independent risk factor for 28-day mortality in HBV-ACLF. Meanwhile, the AUROC analysis demonstrated that serum CXCL1 [0.741 (0.669–0.804)] might be a reliable prognostic biomarker for patients with HBV-ACLF.Conclusions: Overall, serum CXCL1 can serve as a biomarker indicating the severity of disease and prognosis for patients with HBV-ACLF. CXCL1 might also be a therapeutic target in this disease.

show abstract

Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment

Lim

Kwang

et al. 2022

Biomaterials

View full text Add to dashboard Cite

An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma

Cited by 10 publications

References 34 publications

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells

Serum CXCL1 Is a Prognostic Factor for Patients With Hepatitis B Virus–Related Acute-On-Chronic Liver Failure

Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment

Contact Info

Product

Resources

About